You are here

  • Home
  • Archive
  • Volume 70, Issue 11
  • Performance of the new 2011 ACR/EULAR remission criteria with tocilizumab using the phase IIIb study TAMARA as an example and their comparison with traditional remission criteria

Article info

Article menu
Clinical and epidemiological research
Concise report
Performance of the new 2011 ACR/EULAR remission criteria with tocilizumab using the phase IIIb study TAMARA as an example and their comparison with traditional remission criteria

Authors

  1. Correspondence to Christof Iking-Konert, Department of Medicine III, Nephrology and Rheumatology, Universitätsklinikum UKE, 20246 Hamburg, Germany; c.iking-konert{at}uke.de
View Full Text

Citation

Iking-Konert C, Aringer M, Wollenhaupt J, et al
Performance of the new 2011 ACR/EULAR remission criteria with tocilizumab using the phase IIIb study TAMARA as an example and their comparison with traditional remission criteria
Annals of the Rheumatic Diseases 2011;70:1986-1990.

Publication history

  • Accepted June 13, 2011
  • First published August 29, 2011.
Online issue publication 
October 25, 2017

  • Web Only Data

    Files in this Data Supplement:

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions This paper is freely available online under the BMJ Journals unlocked scheme, see http://ard.bmj.com/info/unlocked.dtl